The overall objective of these studies is to develop an effective immunotherapeutic regimen to control neoplastic growth in situations which mimic clinical presentation in human cancer. To date, extracted tumor-specific transplatation antigens (TSTA) from methylcholanthrene (MCA)-induced murine sarcomas of moderate antigenicity used in various combinations with cyclophosphamide and intrasplenically delivered interleukin-2 (IL-2) have reduced neoplastic progression in models of local subcutaneous disease, including retardation of primary outgrowth, augmentation of sinecomitant immunity, eradication of residual disease and amelioration of established disease, and in models of pulmonary metastasis due to artificial or spontaneous, hematogenous dissemination. The proposed studies will test the efficacy of more purified antigens, as well as the benefits of maneuvers to augment immunogenicity, including coupling to monocytes/macrophages or to liposomal carries, as well as cross-linking of TSTA by aggregation, glutaraldehyde, or immobilization on beads. Purification of TSTA epitopes has been achieved by the use of preparative isoelectric focusing, high performance gel permeation chromatography, preparative isotachophoresis and affinity chromatography with monoclonal anti-murine mammary tumor virus antibody. The effects of immunostimulation with muramyl tripeptide in native or liposomal form with treatment in vivo and/or in vitro will be compared and combined with the documented effects of IL-2. The nature of host resistance and effects of TSTA immunotherapy will be dissected by measuring circulating antigen levels, using a monoclonal anit-MCA TSTA antibody, and by expanding sensitized T-cell populations from virgin, immunized or tumor-bearer, syngeneic murine hosts. Expanded T-cell populations, already generated in preliminary studies, will be used for systemic immunotherapy combined with the other agents. In addition, the proposed studies will extend the immunotherapy experiments to a non-immunogenic MCA sarcoma and to epithelial murine colon adenocarcinomas, based on the hypothesis that failure to achieve host resistance during natural in vivo progression is due to insufficient immunogenic antigen presentation, to release of suppressogenic determinants, and/or to a requirement for concomitant immunostimulation. In sum, these experiments will extend the horizons of immunotherapeutic intervention with extracted and purified tumor antigens from models of moderate antigenicity and modest tumor burden, to models of poorly- or non-immunogenic neoplasms present in large body tumor burdens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA029592-07
Application #
3168784
Study Section
Immunobiology Study Section (IMB)
Project Start
1981-03-15
Project End
1988-02-29
Budget Start
1987-03-01
Budget End
1988-02-29
Support Year
7
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Komichi, H; Smith, S; Kahan, B D (1992) Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide. Arch Surg 127:1417-23
Naito, K; Nomi, S; Komichi, H et al. (1992) Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2. Cancer Detect Prev 16:321-7
Kahan, B D (1991) Transplantation timeline. Mankind's three millennia--one maverick's three decades in the struggle against biochemical individuality. Transplantation 51:1-21
Naito, K; Oka, T; Nomi, S et al. (1989) Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma. Jpn J Cancer Res 80:1119-26
Naito, K; Pellis, N R; Kahan, B D (1988) Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones. Cell Immunol 111:216-34
Naito, K; Pellis, N R; Kahan, B D (1988) Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res 48:101-8
Naito, K; Pellis, N R; Kahan, B D (1987) Expansion of tumor-specific cytolytic T lymphocytes using in vitro restimulation with tumor-specific transplantation antigen. Cell Immunol 108:483-94
Nomi, S; Naito, K; Kahan, B D et al. (1986) Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice. Cancer Res 46:6111-5
Nomi, S; Pellis, N R; Kahan, B D (1985) Antigen-specific therapy of experimental metastases. Cancer 55:1296-302
LeGrue, S J; Pellis, N R; Riley, L B et al. (1985) Biochemical characterization of 1-butanol-extracted murine tumor-specific transplantation antigens. Cancer Res 45:3164-72